<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061542</url>
  </required_header>
  <id_info>
    <org_study_id>C-01-01</org_study_id>
    <nct_id>NCT00061542</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension</brief_title>
  <official_title>Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of BETOPTIC S and Timolol
      Gel-forming solution in pediatric patients. Patients will dose with study drug at 8 am and 8
      pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure
      and pulse checks at each visit. Patients will have a dilated fundus exam and corneal
      measurements taken at first and last visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in IOP</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Betaxolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TGFS 0.25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TGFS 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BETOPTIC S (betaxolol HCl)</intervention_name>
    <description>betaxolol HC)</description>
    <arm_group_label>Betaxolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol Gel-forming Solution (TGFS)</intervention_name>
    <description>timolol maleate 0.25% and 0.5%</description>
    <arm_group_label>TGFS 0.25%</arm_group_label>
    <arm_group_label>TGFS 0.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION:

          -  Children 5 years old and younger

          -  require treatment for glaucoma or ocular hypertension

          -  whose vision is 20/80 or better

          -  have a cup-to-disc ratio of 0.8 or less

        EXCLUSION:

          -  do not have abnormal fixation

          -  IOP greater than 36 mm Hg

          -  significant retinal disease

          -  penetrating keratoplasty

          -  severe ocular pathology

          -  optic atrophy

          -  eye surgery in the past 30 days

          -  cardiovascular abnormalities

          -  hypersensitivity to beta blockers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alcon Call Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Plager DA, Whitson JT, Netland PA, Vijaya L, Sathyan P, Sood D, Krishnadas SR, Robin AL, Gross RD, Scheib SA, Scott H, Dickerson JE; BETOPTIC S Pediatric Study Group. Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. J AAPOS. 2009 Aug;13(4):384-90. doi: 10.1016/j.jaapos.2009.04.017.</citation>
    <PMID>19683191</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2003</study_first_submitted>
  <study_first_submitted_qc>May 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2003</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Betaxolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

